We are an Innovative Biopharmaceutical Company Dedicated to Development of the First-in-clsss Antibody Drugs.
ALMB-0166 reduces the formation of an impenetrable scar at the site of spinal cord injury by reducing the inflammation associated with the injury. This drug preserves the neurological ability for nerves to regenerate and function to be restored.
ALMB-0168 prevents the growth and spread of bone related cancers (osteosarcoma and bone metastases) by releasing ATP into the tumor’s extracellular microenvironment that is unfavorable for tumor progression or migration.
Clinical Trial Approval in Australia
ALMB-0168 has obtained approval from Australia for conducting the first-in-human clinical trial for the treatment of bone cancer and cancer bone metastasis.
Clinical Trial Approval in Australia.
ALMB-0166 has obtained approval from Australia for conducting the first-in-human clinical trial for the treatment of acute spinal cord injury.
ALMB-0168 Granted Rare Pediatric Disease Designation
ALMB-0168 was granted Rare Pediatric Disease Designation by the U.S. FDA
HOW CAN WE HELP?
302 Carnegie Center Drive
Princeton, NJ, 08540